Jan 20, 2017 12:10 PM

Marijuana and Seizures: DEA Prevents Life-Saving Discoveries

In 2015, the American Epilepsy Society (AES) conducted a study that involved 261 patients with treatment-resistant epilepsy, mostly kids and young adults. The most common diagnoses were Dravet syndrome and Lennox-Gastaut syndrome. The scientists used medical marijuana for seizures treatment instead of or along with traditional pharmaceutical therapy.

After three months of CBD treatment, the researchers saw a significant reduction in seizure frequency in 45 percent of cases. Furthermore, by the end of the experiment, 9 percent of patients reported having no seizures at all.

The CBD treatment showed a higher level of efficacy for treating Dravet syndrome: the median overall reduction of seizure frequency among patients with Dravet syndrome was 62.7 percent. And 13 percent of patients diagnosed with Dravet syndrome reported having no seizures by the end of the 12-weeks-long CBD treatment course.

The authors of the study concluded that CBD may be a promising treatment for drug-resistant forms of epilepsy.

Marijuana and Epilepsy: Another Cannabinoid May Be as Beneficial as CBD
Marijuana and Epilepsy: Another Cannabinoid May Be as Beneficial as CBD
Cannabinoids are the chemical compounds of the cannabis plant. Today, scientists know 113 types of cannabinoids. All of them have a broad range of properties and functions. Researchers are mostly focused on studying the two main cannabinoids—THC and CBD.

But, of course, more research is needed in order to make sure that we may use marijuana for seizures and that cannabis-based treatment is both safe and effective. The scientists need to collect more data in order to fully understand the way cannabis affects human brain and body. The problem is that as long as marijuana remains on the Schedule I substances list, no further research may be conducted.

Study Review: How Can Cannabis Treat Epilepsy?
Study Review: How Can Cannabis Treat Epilepsy?
Modern medicine can replace a faulty heart, liver, or kidney. It can sew on a finger or even a whole hand. It can regrow skin in a Petri dish. But the brain's abnormalities remain a secret to it.

To make things even worse, in December 2016, the DEA announced a new code for marijuana extracts and CBD oil in particular. That decision raised serious concerns among medical cannabis patients. Parents of children suffering from drug-resistant epilepsy were more than just concerned; many were outraged.

DEA Says CBD Oil Is Schedule I Substance. What's Next?
DEA Says CBD Oil Is Schedule I Substance. What's Next?
Last week, DEA released a Federal Register that included, among other things, a new Administration Controlled Substances Code Number for what they call ‘‘marihuana extract.’’ According to DEA, the main reason for inventing the new code was to make it easier for the agency to track this type of substances, alongside with “marihuana” and “tetrahydrocannabinols.”

Although some experts insist that DEA's decision does not change the legal status of marijuana extracts and only confirms that all kinds of cannabis plants remain illegal, the agency's move poses a serious threat to medical cannabis.

Before the implementation of the new code for “marihuana extracts,” as the DEA calls it, there was a loophole in the law that allowed scientists and most importantly patients with the treatment-resistant forms epilepsy to use hemp-derived CBD oil. But the Federal Register, released last month, includes a few lines stating that marijuana extracts “derived from any plant of the genus Cannabis,” including hemp, are all Schedule I substances.

Basically, this statement shuts down the loophole in the law that existed before, making it illegal to use marijuana oil for seizures, even if it is a non-psychoactive CBD oil derived from hemp.

At the same time, other countries acknowledge the medicinal effect CBD oil has on patients with epilepsy and other severe conditions. In Australia, for example, medical marijuana was legalized this fall. Currently, Australian scientists study the effects of both THC and CBD on patients with cancer, epilepsy, and other severe diagnoses.

Australia Uses Tilray Products for New Chemotherapy Trial
Australia Uses Tilray Products for New Chemotherapy Trial
Australian researchers are now recruiting cancer patients to study how medical marijuana can prevent vomiting and nausea caused by chemotherapy.

And in the UK, a group of scientists is working on an extensive study on medical cannabis and arthritis. Both countries will hold massive clinical trials that will help the scientists understand if cannabis may be used as an effective and harmless treatment.

UK Finally Launches Study on Cannabis for Arthritis
UK Finally Launches Study on Cannabis for Arthritis
Cannabis helps hundreds of patients find relief from inflammation and pain. Although there have been plenty of studies about marijuana’s potential, there is always a great need for more detailed research and additional trials.

Similar news
CBD Oil Use in Pediatrics
Though today we all have heard about the health benefits of CBD and the component's potential in pediatrics. However, it was not always this way. When did we start studying this component of cannabis and its use in medicine?
Jun 27, 2016 9:20 AM
Cannabis Oil Cancer Research Shows Benefits of Marijuana-Based Treatment
Numerous studies show that hemp oil may be beneficial for cancer patients: it gives them a temporary pain relief, helps reduce nausea and anxiety. Still, we need more cannabis oil cancer research in order to get unquestionable evidence of marijuana's efficiency.
Apr 14, 2016 8:10 AM
York Hospital Makes Successful Medical Marijuana Studies on Children With Epilepsy
According to the experiment at Wellspan Health in York County, Pennsylvania, medical marijuana can effectively alleviate seizures in children. This can turn to be one of the most successful studies on marijuana.
Apr 6, 2016 4:10 PM